Dr. Tara Tabatabaie, an attorney and a scientist, brings an extremely unique combination of legal
and scientific expertise to cases where science and scientific evidence are at the heart of the
issues in question. Dr. Tabatabaie has served as a member of the Plaintiffs Steering Committees
and Science Committees of a number of national, multi-district litigations against large
pharmaceutical and chemical companies, including, In Re: Abbott Laboratories, et al., Preterm
Infant Nutrition Products Liability Litigation, MDL 3026, against Abbott and Reckitt; In re
Roundup Products Liability Litigation, MDL 2741,against Monsanto and Bayer; In Re: Actos
(Pioglitazone) Products Liability Litigation, MDL 2299, ; against Takeda and Eli Lilly, In Re:
Fluoroquinolone Products Liability Litigation, MDL 2642, against Johnson & Johnson and Bayer,;
and In Re: Avandia Marketing, Sales Practices, and Products Liability Litigation, MDL 1871,
against GlaxoSmithKline.
Dr. Tabatabaie’s scientific expertise and unique skill set have made significant contributions
to the successful resolution of these cases, many of which resulted in multi-billion-dollar
settlements for the plaintiffs. Her ability to pinpoint critical scientific evidence, and her work
regarding scientific experts in the cases she has been involved in have enabled plaintiffs to
successfully develop and advance scientific theories that withstand attacks by experts retained
by defendants, and defendants’ Daubert challenges.
Dr. Tabatabaie earned her PhD in Chemistry from University of Oklahoma in 1992, and her Juris
Doctor degree, Magna Cum Laude, from Oklahoma City University in 2007. She was the
recipient of multiple awards and honors during her studies at both institutions.
Prior to starting her legal career, Dr. Tabatabaie was a senior research scientist at the Oklahoma
Medical Research Foundation in Oklahoma City. In that position, she studied the biomedical
processes involved in a variety of diseases, including cancer, diabetes, stroke, heart disease,
Alzheimer’s disease, and various environmental toxins. Dr. Tabatabaie is the author of numerous
scientific articles and book chapters and has served as the peer reviewer for several prestigious
scientific journals.
Dr. Tabatabaie’s broad knowledge of scientific mechanisms involved in disease and injury, combined with her legal skills, has benefited plaintiffs in pharmaceutical and environmental cases on a national level. Working as a part of leadership in these cases, Dr. Tabatabaie’s unique set of skills has been critical to the success of plaintiffs in a number of multidistrict litigations (MDLs).
Dr. Tabatabaie has been named to the prestigious Lawdragon’s “500 Leading
Plaintiff Consumer Lawyers” list.
- Oklahoma (2007)
- Federal Courts for the Western District of Oklahoma and
Northern District of Oklahoma
- The Court of Appeals for the Tenth Circuit
- Juris Doctorate, Magna Cum Laude, Oklahoma City University School of Law
- Ph.D., Chemistry University of Oklahoma
- Oklahoma Bar Association
- American Bar Association
- American Association for Justice
- Oklahoma Association for Justice
- American Constitution Society
- American Association for Advancement of Sciences
- American Chemical Society
- Society of Free Radical Biology and Medicine
- American Diabetes Association
Due to her extensive biomedical research experience, Dr. Tabatabaie is frequently
requested to lecture and educate the legal community on the scientific issues
involved in pharmaceutical litigation. Her latest contribution is an article
published in the Journal of the American Association for Justice, Trial, entitled
“Decoding General Causation Data.”
- Tabatabaie, T., Vasquez-Weldon, A.M., Moore, D.R., & Kotake, Y. (2003) Free
radicals and the pathogenesis of Type 1 Diabetes: Cytokine-mediated
generation of free radicals by beta cells. Diabetes, 52: 1994-99.
- Hensley, K., Tabatabaie, T., Stewart, C.A., Pye, Q.N., and Floyd, R.A. (1997)
Nitric oxide and derived species as toxic agents in stroke, AIDS dementia,
and chronic neurodegenerative disorders. Chemical Research in
Toxicology, 10:527-532.
- Tabatabaie, T., Kotake, Y., Wallis, G., Jacob, J., and Floyd, R.A. (1997) Spin
trapping agent phenyl N tert-butylnitrone protects against the onset of
drug-induced insulin-dependent diabetes mellitus. FEBS Letters, 407:148-
152.
- Tabatabaie, T., Stewart, C., Pye, Q.N., Kotake, Y., and Floyd, R.A. (1996) In
Vivo trapping of nitric oxide in the brain of neonatal rats treated with the
HIV-1 envelope protein GP 120: Protective effects of α-phenyl-Tert-
butylnitrone. Biochem. Biophys. Res. Commun., 221:386-390.
- Tabatabaie, T., and Floyd, R.A., (1996) Protein damage and oxidative stress.
IN Cellular Aging and Cell Death. (Holbrook, N.J., Martin, G.L., Lockshin,
R.A., eds.) Wiley-Liss, Inc., pp 35-49.
- Tabatabaie, T., Goyal, R.N., Blank, C.L., and Dryhurst, G. (1993) Further
insights into the mechanisms by which 5,7-Dihydroxytryptamine expresses
its neurotoxicity. Journal of Medicinal Chemistry, 36:229-236.
- Member, Board of Directors, Sustainable Oklahoma City
- Past Member, Board of Directors, Juvenile Diabetes Research Foundation